• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Difelikefalin associated with reductions in itch intensity and improvements in itch-related quality of life

byThomas SuandDeepti Shroff Karhade
January 18, 2020
in Dermatology, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this double-blind phase 3 trial involving patients undergoing hemodialysis who had moderate-to-severe pruritus, a clinically significant decrease in itching intensity was noted in a greater percentage of patients in the difelikefalin group than in the placebo group.

2. On average, improvements in itching-related quality of life were also greater in the difelikafalin group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Pruritus affects the majority of patients undergoing hemodialysis and is associated with reduced quality of life and increased risk of death. While the pathogenesis of uremic pruritus is not yet fully understood, a number of hypotheses have been posited, including endogenous opioid system imbalance. Difelikefalin is a peripherally restricted, selective kappa opioid receptor agonist that has produced clinically significant benefits in phase 2 trials involving patients undergoing hemodialysis who had moderate-to-severe pruritus. This phase 3 trial found that difelikefalin resulted in dramatic reductions in itching intensity as well as significant improvements in itch-related quality of life, corroborating the findings of earlier-stage trials. Adverse events, although high in both groups, occurred slightly more frequently in the treatment group, with diarrhea, dizziness, and vomiting being the most common. Dysphoria and hallucinations were notably absent, indicating a possible safety advantage of peripherally restricted kappa opioid agonists versus mu opioid and centrally acting kappa opioid receptor agonists. While the robustness of this data was confirmed through sensitivity analyses, these findings have limited generalizability due to specific eligibility criteria and a relatively short follow up.

Click here to read the study in NEJM

Relevant Reading: Treatment of Uremic Pruritus: A Systematic Review

In-Depth [randomized controlled trial]: In this multicenter, double-blind, phase 3 trial, 378 patients undergoing hemodialysis who had moderate-to-severe pruritus were stratified according to history of prespecified medical conditions and concomitant antipruritic use, and randomly assigned in a 1:1 ratio to receive either difelikefalin at a dose of .5 mcg/kg or placebo three times per week for 12 weeks. At baseline, patients scored similarly on the 24 hour Worst Itching Intensity Numerical Rating Scale (WI-NRS), averaging 7.1±1.4 in the difelikefalin group and 7.3±1.6 in the placebo group. At week 12, a significantly greater proportion of patients in the treatment group showed an improvement (decrease) of at least 3 points from baseline in the weekly mean score on the 24-hour WI-NRS versus placebo (49.1% vs. 27.9%; relative risk, 1.65; 95% confidence interval, 1.26 to 2.14; P<0.001). The treatment group also experienced greater improvements in quality of life according to multidimensional metrics such as least-squares mean change from baseline in 5-D itch scale total score (-5.0±0.3 vs. -3.7±0.3) and least-squares mean change from baseline in Skindex-10 total score (-17.2±1.3 vs. -12.0±1.2) (all P-values <0.001). Of the five dimensions of itch, four (distribution, duration, degree, and direction) displayed a between-group difference in favor of difelikefalin. Adverse events leading to discontinuation of treatment were more common in the difelikefalin group (7.9% vs. 4.8%).

RELATED REPORTS

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Spirituality-oriented psychological counseling may reduce fear of death among hemodialysis patients

Wellness Check: Spirituality

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: difelikafalinend-stage renal disease (ESRD)hemodialysispruritisselective kappa opioid receptor agonist
Previous Post

Electronic health record-based weight maintenance coaching

Next Post

Peroral endoscopic myotomy in patients with idiopathic achalasia

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Nephrology

Spirituality-oriented psychological counseling may reduce fear of death among hemodialysis patients

March 28, 2022
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women
Chronic Disease

Wellness Check: Spirituality

March 24, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Poor humoral response observed in patients undergoing hemodialysis following a single dose of the BNT162b2 SARS-CoV-2 vaccine

September 7, 2021
Next Post
Peroral endoscopic myotomy in patients with idiopathic achalasia

Peroral endoscopic myotomy in patients with idiopathic achalasia

Uninterrupted warfarin therapy safe for endovascular procedures

Total hip arthroplasty versus hemiarthroplasty for management of hip fractures

Association of Intrinsic Brain Architecture With Changes in Attentional and Mood Symptoms During Development

Association of Intrinsic Brain Architecture With Changes in Attentional and Mood Symptoms During Development

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]
  • Daily disposable contact lenses may lower risk for Acanthamoeba keratitis
  • Vitamin D deficiency may be associated with sleep disorders in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.